Korro Bio sings to the tune of $116M for its OPERA RNA editing program - Fierce Biotech

Retrieved on: 2022-01-05 18:43:30

Tags for this article:

Click the tags to see associated articles and topics

Korro Bio sings to the tune of $116M for its OPERA RNA editing program - Fierce Biotech. View article details on hiswai:

Excerpt

funding RNA Cell & Gene Therapy gene editing gene therapy Korro Bio Invus Atlas Venture New Enterprise Associates venture capital.

Article found on: www.fiercebiotech.com